The news comes as the FSA has published the report analysing 20 years of data on AMR in Campylobacter from retail chicken in the UK. The study aimed to assess any trends during this 20-year period and provides a baseline against which to evaluate future, hoped-for reductions in AMR.
AMR is when bacteria adapt to become resistant to the killing effects of antimicrobials, such as antibiotics. This resistance subsequently makes such infections in humans more difficult to treat using drugs.
It can develop in any bacteria, including Campylobacter, which is the main cause of bacterial food poisoning in the developed world. The FSA said it estimates that there are in excess of half a million cases annually in the UK.
The FSA’s science lead in Microbiological Risk Assessment, Dr Paul Cook, said: “While the data shows a marked increase in AMR in Campylobacter to certain antimicrobials, it is encouraging that there has been no significant increase in resistance since 2014.
“Any increase of AMR in Campylobacter is a concern and continued surveillance is essential. We will continue to carry out AMR surveillance in chicken and other meats and to monitor any long-term trends in resistance, while promoting good food hygiene practice to reduce exposure to AMR bacteria and protect consumer safety.”
Since its formation in 2000, the FSA has commissioned several UK-wide retail surveys and sampling studies that involved testing for Campylobacter in chicken.
Key findings from this report vary between the five main types of antimicrobial drugs included in the study. Resistance to quinolones (ciprofloxacin and nalidixic acid) and tetracycline was common in the most prevalent types of Campylobacter from chicken (Campylobacter jejuni and Campylobacter coli). In comparison, resistance to erythromycin and streptomycin was much rarer in the Campylobacter isolates examined. Gentamicin resistance was very rare.